SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (471)6/25/2004 1:49:11 PM
From: Biomaven   of 933
 
after a first line therapy that has such associated toxicity

All the first line traditional chemo therapies have substantial toxicity of one form or another. None work that well in advanced disease - hence the excitement about Erbitux and Avastin.

Juggling combinations of chemo drugs is always a learning experience. Sometimes getting just the right combination and dosing makes a dramatic difference - testicular cancer is a good example, where long term responses went from close to zero to something like 90% with essentially no new drugs, just different doses and combinations of existing ones.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News